-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BgVTF4fUBhOl6xiBmXe5Dset3hNbZ56RANEDbb4JMKBHTCJcoJoU8bEbnSNs5/iV g3vfp0kjl2dhHxNFqcVidA== 0001169232-05-000548.txt : 20050208 0001169232-05-000548.hdr.sgml : 20050208 20050208172950 ACCESSION NUMBER: 0001169232-05-000548 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20041111 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20050208 DATE AS OF CHANGE: 20050208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENZON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000727510 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 222372868 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-12957 FILM NUMBER: 05585123 BUSINESS ADDRESS: STREET 1: 685 ROUTE 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 7329804500 MAIL ADDRESS: STREET 1: C/O DORSEY & WHITNEY LLP STREET 2: 250 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10177 FORMER COMPANY: FORMER CONFORMED NAME: ENZON PHARMACEUTICAL INC DATE OF NAME CHANGE: 20021210 FORMER COMPANY: FORMER CONFORMED NAME: ENZON INC DATE OF NAME CHANGE: 19920703 8-K/A 1 d62133_8k-a.htm AMENDMENT

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K/A

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) February 2, 2005 (November 11, 2004)

 

ENZON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

0-12957

22-2372868

(State or other jurisdiction of
incorporation)

(Commission
File Number)

(IRS Employer
Identification)

 

 

685 Route 202/206, Bridgewater, New Jersey 08807

(Address of principal executive offices) (Zip Code)

 

(Registrant’s telephone number, including area code: (908) 541-8600

 

______________________________________________________________________

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

|_|

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

|_|

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

|_|

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

|_|

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

 

Enzon Pharmaceuticals, Inc. hereby amends its Form 8-K filed on November 15, 2004 to disclose the committees of the Board of Directors to which Dr. Goran A. Ando and Victor P. Micati have been appointed. The remainder of the Form 8-K is unchanged.

 

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

 

As previously reported on the Current Report on Form 8-K, filed November 15, 2004, the Board of Directors of Enzon Pharmaceuticals Inc. elected Dr. Goran A. Ando and Victor P. Micati to its Board of Directors. On February 2, 2005, the Board of Directors appointed Dr. Ando to serve on the Executive Committee, the Compensation Committee and the Scientific Committee. Also on February 2, 2005, the Board of Directors appointed Mr. Micati to serve on the Executive Committee, the Governance and Nominating Committee and the Scientific Committee.

 


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: February 8, 2005

 

By: /s/ Kenneth J. Zuerblis    

 

Kenneth J. Zuerblis

 

 

Vice President, Finance and

 

Chief Financial Office

 

 

 

 -----END PRIVACY-ENHANCED MESSAGE-----